Abstract
Renal medullary carcinoma (RMC) is a rare and aggressive malignancy seen primarily in patients with sickle-cell trait. We report a complete response to carboplatin, paclitaxel, and gemcitabine in a patient with advanced metastatic RMC.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary*
-
Child
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Gemcitabine
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / secondary*
-
Male
-
Paclitaxel / administration & dosage
-
Sickle Cell Trait / drug therapy*
-
Sickle Cell Trait / pathology*
-
Treatment Outcome
Substances
-
Deoxycytidine
-
Carboplatin
-
Paclitaxel
-
Gemcitabine